Clinical Trial Information(data fromhttps://clinicaltrials.gov, updated on 2024-05-22) NCT NumberRecruitmentConditionsSponsor/CollaboratorsStart DatePhases NCT01681368Terminated Epithelial Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms National Cancer Institute (NCI)|National Institutes of Health Cl...
Top right: crystal structure of Hsp90 in a complex with geldanamycin (PDB ID: 1YET), the first Hsp90 inhibitor to enter clinical trials. Bottom right: superimposition of p53 peptide and Nutlin-2 (one of the first identified potent MDM2–p53 inhibitors) bound to the N-terminal domain of ...
It has been shown before, however, that IAP antagonists can also co-stimulate effector T-cells and NK cells, thus furthering the potential clinical impact of IAP antagonists55,56,57. In fact, a clinical trial combining Pembrolizumab and Birinapant is currently recruiting (ClinicalTrials.gov: NCT...
Here, we report the preclinical characterization of birinapant (TL32711), a bivalent SMAC-mimetic compound currently in clinical trials for the treatment of cancer. Birinapant bound to the BIR3 domains of cIAP1, cIAP2, XIAP, and the BIR domain of ML-IAP in vitro and induced the auto...
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32. Article Google Scholar Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al. cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing ...
clinical trials. Addition of the nucleoside analog gemcitabine to platinum drugs is one such strategy based on synergism of these two drugs in vitro when treating platinum-resistant ovarian cancer cells.25,26But when this combination therapy was tested in clinic, overall response rates were low.27...